Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern

Loading...
Loading...
  • Sanofi SA SNY said the next-gen COVID-19 vaccine candidate it has developed with GSK Plc GSK in two trials showed a potential to protect against the virus's main variants of concern when used as a booster.
  • In the Phase 3 VAT02 Cohort 2 study, the vaccine candidate showed a 15-fold increase against the parent virus and a 30-fold increase against Beta strain in adults previously primed with mRNA COVID-19 vaccines. 
  • In particular, against omicron, preliminary data show a 40-fold increase against BA.1. 
  • The Sanofi-GSK next-generation booster candidate generated double the number of neutralizing antibodies against omicron BA.1 and BA.2 compared to the original parent virus booster.
  • Related: EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine.
  • An independent COVIBOOST study demonstrated that Sanofi-GSK next-generation booster generated a higher immune response after two doses of Pfizer Inc PFEBioNTech's SE BNTX COVID-19 shot than Pfizer-BioNTech's booster or the Sanofi-GSK first-generation booster.
  • In this study, which included 247 subjects, all three vaccines elicited neutralizing antibodies against the omicron BA.1 variant, with the highest responses generated by the Sanofi-GSK next-generation candidate. 
  • Across both studies, the Sanofi-GSK next-generation vaccine candidate was well-tolerated, with a favorable safety profile. 
  • In the VAT02 cohort 2 study, low numbers of Grade 3 reactions were reported, all transient and non-severe.
  • Price Action: SNY shares are down 1.16% at $50.32, and GSK stock is down 2.47% at $42.72 during the premarket session on the last check Monday.
  • Photo by hakan german from Pixabay
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...